Chardan Capital reissued their buy rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) in a report published on Friday.
“We now raise our PT to $175, after: (1) increasing the patisiran probability of success to 97%, and (2) lowering the Alnylam WACC to 8% to reflect further RNAi therapeutics platform de-risking. We now update our Alnylam patient-based and other models to reflect recent positives, while consolidating views from recent Chardan macro research (e.g. on novel lipid-lowering therapies). (See Figures 3-7.) Notably, a near- best-case safety and efficacy profile emerged from the pivotal APOLLO trial (as discussed in our 20 September 2017 research); and, Alnylam proceeded to file patisiran in an expeditious fashion. We thus newly model a 97% probability of success (POS) for patisiran and $1.77 billion in 2030E risk-adjusted franchise sales (patisiran and follow ons). We now increase the POS of givosiran, to 80% ($540 million in 2030E sales) from 40% in our previous model, given the product’s progress ahead of our expectations.”,” the firm’s analyst commented.
Other equities analysts have also issued research reports about the stock. B. Riley reduced their price target on shares of Alnylam Pharmaceuticals to $220.00 and set a buy rating for the company in a research report on Wednesday, November 8th. Ladenburg Thalmann Financial Services restated a buy rating and set a $146.00 price target (up previously from $90.00) on shares of Alnylam Pharmaceuticals in a research report on Thursday, September 21st. Sanford C. Bernstein restated a buy rating and set a $135.00 price target (up previously from $94.00) on shares of Alnylam Pharmaceuticals in a research report on Thursday, September 21st. Needham & Company LLC restated a buy rating and set a $152.00 price target (up previously from $125.00) on shares of Alnylam Pharmaceuticals in a research report on Friday, November 3rd. Finally, FBR & Co started coverage on shares of Alnylam Pharmaceuticals in a research report on Monday, October 30th. They set a buy rating and a $150.00 price target for the company. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of Buy and an average target price of $121.20.
Alnylam Pharmaceuticals (ALNY) traded up $0.84 on Friday, reaching $124.83. 883,800 shares of the company traded hands, compared to its average volume of 778,323. The company has a market capitalization of $12,770.00, a price-to-earnings ratio of -23.78 and a beta of 2.98. The company has a debt-to-equity ratio of 0.14, a quick ratio of 9.83 and a current ratio of 9.83. Alnylam Pharmaceuticals has a one year low of $35.98 and a one year high of $147.63.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.34) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.23) by ($0.11). The company had revenue of $17.10 million for the quarter, compared to the consensus estimate of $28.15 million. Alnylam Pharmaceuticals had a negative net margin of 664.70% and a negative return on equity of 46.94%. Alnylam Pharmaceuticals’s quarterly revenue was up 24.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.21) EPS. equities analysts predict that Alnylam Pharmaceuticals will post -5.29 EPS for the current year.
In related news, VP Michael Mason sold 36,745 shares of the firm’s stock in a transaction that occurred on Thursday, January 4th. The shares were sold at an average price of $131.59, for a total value of $4,835,274.55. Following the sale, the vice president now directly owns 6,352 shares of the company’s stock, valued at $835,859.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Akshay Vaishnaw sold 33,666 shares of the firm’s stock in a transaction that occurred on Monday, October 30th. The shares were sold at an average price of $121.46, for a total transaction of $4,089,072.36. Following the completion of the sale, the executive vice president now directly owns 45,201 shares in the company, valued at $5,490,113.46. The disclosure for this sale can be found here. Over the last three months, insiders sold 274,075 shares of company stock worth $35,356,089. Insiders own 4.30% of the company’s stock.
Institutional investors and hedge funds have recently made changes to their positions in the stock. California Public Employees Retirement System raised its stake in Alnylam Pharmaceuticals by 14.4% in the second quarter. California Public Employees Retirement System now owns 126,700 shares of the biopharmaceutical company’s stock valued at $10,106,000 after purchasing an additional 15,900 shares in the last quarter. Verition Fund Management LLC purchased a new stake in Alnylam Pharmaceuticals in the second quarter valued at approximately $1,060,000. Gotham Asset Management LLC purchased a new stake in Alnylam Pharmaceuticals in the second quarter valued at approximately $772,000. Bradley Foster & Sargent Inc. CT raised its stake in Alnylam Pharmaceuticals by 100.1% in the third quarter. Bradley Foster & Sargent Inc. CT now owns 8,235 shares of the biopharmaceutical company’s stock valued at $968,000 after purchasing an additional 4,120 shares in the last quarter. Finally, Nexthera Capital LP purchased a new stake in Alnylam Pharmaceuticals in the second quarter valued at approximately $8,375,000. 88.41% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: This piece of content was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another site, it was stolen and reposted in violation of US and international copyright law. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/01/22/chardan-capital-reaffirms-buy-rating-for-alnylam-pharmaceuticals-alny.html.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.